A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

October 12, 2011

Waist and Triglyceride Measurements Help Gauge Cardiovascular Disease Risk in HIV

According to a new study conducted by Canadian and Italian researchers published online by PLoS One, two simple measurements can help determine if you’re at an increased risk for cardiovascular disease (CVD): your waist circumference combined with your triglyceride level.

HIV-positive men with both a waist circumference of 35.5 inches or higher and a triglyceride level above 175 milligrams per deciliter (mg/dL) of blood are at an increased risk for CVD, compared with HIV-positive men with lower measurements, the study suggests. Among HIV-positive women, having both a waist circumference above 33.5 inches and a triglyceride level above 130 mg/dL signifies an increased risk of CVD.

Research has consistently shown that people living with HIV, particularly those with various symptoms consistent with lipodystrophy, face an increased risk of CVD compared with their HIV-negative peers. What hasn’t been clear is which laboratory values and other measurements to use—readily and easily—to determine whether a person living with HIV is, in fact, at risk for CVD-related health problems. 

One particular set of measurements is recommended for HIV-negative individuals. It is known as the hypertriglyceridemic waist phenotype, a combination of two measurements: a person’s waist circumference and his or her triglyceride level.

To explore the value of these measurements in a population of people living with HIV, Peter M. Janiszewski, PhD, of Queen’s University in Kingston, Ontario, and his colleagues analyzed waist circumference and triglyceride data collected at a single time point from 1,481 HIV-positive men and 841 HIV-positive women receiving metabolic-related care between 2005 and 2009.

Based on cut-off values that have previously been shown to be associated with CVD risk, a high waist circumference was considered to be 90 cm (35.5 inches) for the men and 85 cm (33.5 inches) for the women included in the analysis. High triglycerides were 2.0 micromols per liter (175 mg/dL, the common American measurement) for men and 1.5 mmol/L (130 mg/dL) for women.

Roughly 27 percent of the men and 20 percent of the women had both high waist circumferences and high triglyceride levels. Compared with those with high waist circumferences only, high triglycerides only, or waist circumferences and triglyceride levels below the defined cut-offs, individuals with both high waist circumferences and triglycerides were significantly more likely to have established risk factors for CVD. These factors included type-2 diabetes, an increased Framingham risk score and metabolic syndrome, which is a cluster of symptoms such as increased blood pressure, a high blood sugar level, excess body fat around the waist and/or abnormal cholesterol levels.

Specifically, the prevalence of metabolic syndrome was significantly higher in the men with high waist circumferences and triglycerides than in any other waist circumference/triglyceride group: 48 percent compared with 3.6 to 31.9 percent. Additionally, the prevalence of type-2 diabetes was highest in the high waist circumference/triglyceride group compared to all groups (16.2 percent versus 5.5 to 7.2 percent). The average Framingham risk score was also significantly higher in the high waist circumference/triglyceride men’s group in comparison to all other groups (10.3 percent versus 5.8 to 9.5 percent).

“The combination of waist circumference and triglycerides was shown to discriminate high-risk and low-risk HIV-infected men and women,” the authors conclude. “The present findings suggest a utility of waist circumference combined with triglyceride levels as a simple clinical tool for discerning the severity of lipodystrophy and associated cardiovascular risk.”

Search: waist circumference, triglycerides, hypertriglyceridemic waist phenotype, diabetes, Framingham, metabolic syndrome, cardiovascular disease, risk


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

ladanak, , 2011-10-20 16:54:03
i have cirrosis of liver and have been told not to take cholesterol and triglycerides meds.has anyone else had this setback .i have big belly and high triglycerides

jjbearphx, Phoenix, 2011-10-13 11:56:39
Another apples and oranges study. there is no break down for body somatic types, ectomorphs always have a higher risk of CVD than the other 2 types. I wonder which anti statin medication Pharmaceutics company paid for the study? Flat earth reasearch ,I drop a sphere on the ground and it dose not roll therefore the earth is flat. Cell ageing is not taken into account, with the latest research on this wile I am 49 mitochondrialy I am 80-105. Age is also a part of CVD

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chrisf
    san jose
    California


    TanyaB
    Delray Beach
    Florida


    sable22
    Orlando
    Florida


    ZealousBrother
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.